Sage Journals: Discover world-class research

Abstract

Tissue banking programs fail to meet the demand for human organs and tissues for transplantation into patients with congenital defects, injuries, chronic diseases, and end-stage organ failure. Tendons and ligaments are among the most frequently ruptured and/or worn-out body tissues owing to their frequent use, especially in athletes and the elderly population. Surgical repair has remained the mainstay management approach, regardless of scarring and adhesion formation during healing, which then compromises the gliding motion of the joint and reduces the quality of life for patients. Tissue engineering and regenerative medicine approaches, such as tendon augmentation, are promising as they may provide superior outcomes by inducing host-tissue ingrowth and tendon regeneration during degradation, thereby decreasing failure rates and morbidity. However, to date, tendon tissue engineering and regeneration research has been limited and lacks the much-needed human clinical evidence to translate most laboratory augmentation approaches to therapeutics. This narrative review summarizes the current treatment options for various tendon pathologies, future of tendon augmentation, cell therapy, gene therapy, 3D/4D bioprinting, scaffolding, and cell signals.

Keywords

Regenerative medicine tissue engineering tendon repair tendon augmentation bio-fabrication 3D/4D bioprinting

Introduction to tissue engineering and regenerative medicine (TERM)

In recent years, advances in biomedical research have produced significant milestones in new drug discovery, medical devices, and clinical procedures. One breakthrough of biomedical research advancements in the past three decades was the emergence of TERM. The intention of this field is based on the idea that tissue and organ reconstruction can restore patient’s normal lives after organ loss/injury. The terms tissue engineering (TE) and regenerative medicine (RM) are typically used separately and interchangeably to mean one thing (TERM), although there is a marked difference in the technicalities of the fields. TE focuses more on creating in vitro bio-artificial tissues or cellular products to repair tissues within the body and involves in vivo alteration of cell growth and function through the implantation of suitable cells isolated from donor tissue and biocompatible scaffold materials.¹ In contrast, RM focuses on endogenous tissue formation.² The three most important components of TERM are biomaterials, cells, and signals.³

Although a well-defined field (TERM) has recently been developed, its foundation can be traced back to the year 300 BC in Indian writings that described skin grafting in Sanskrit texts.⁴ TERM became recognized in the mid-1950s when the first kidney transplant between identical twin brothers was successfully performed.⁵ The field aims to solve problems related to diverse backgrounds, such as acute or chronic degenerative diseases, trauma, aging, and congenital defects, and hence overlaps with other disciplines, including biomaterials, nanotechnology, stem cell biology, developmental biology, engineering, and medicine.⁶ In the field of medicine, orthopedics has greatly benefited from the technological evolution of TERM. However, to date, tendon TE and regeneration research has been limited and lacks the much-needed human clinical evidence to translate most laboratory augmentation approaches to therapeutics. Previous review articles^7–13 have also performed a similar review; however, the current study conducted an extensive review of current literature to help with the limited translation of tendon augmentation in clinical practice and provide a better understanding of tendon repair in TERM.

Search strategy

A review of published articles on tendon augmentation was performed. Scientific literature was searched in relevant databases (Google Scholar, Scopus, PubMed, and Web of Science) using the terms “(regenerative medicine) AND (tissue engineering) AND (tendon repair OR tendon augmentation) AND (bio-fabrication)”. The search was conducted with publication language restricted to English. The titles of articles were reviewed, followed by the abstracts and full texts. After the removal of duplicates and unrelated papers, 96 articles were used in this narrative review. This article does not contain any studies with human participants or animals performed by any of the authors. Therefore, ethical approval and informed patient consent were not required.

TE in tendon/ligament augmentation

TE research in tendon augmentation intensified in the early 1980s, resulting in the first commercial product Gore-Tex Cruciate Ligament prosthesis (WL Gore and Associates, Newark, DE, USA) being approved by the Food and Drug Administration (FDA) on 10 October 1986.¹⁴ Since 1986, more commercial products have been approved, mostly in the USA by the FDA but also in Europe and across the world. Commercial augmentation products are being developed for the increased tendon injury burden from workplaces and age-related conditions, with approximately 30% to 50% of sports injuries involving tendon injuries.¹⁵ Currently, surgical repair remains the gold standard treatment for tendon/ligament rupture. However, the healing process is naturally lengthy relative to that of other soft tissues.^11,16 This is partly because tendons are tissues of high activity with a poor blood supply, supporting fundamental locomotion of the body. As a result, they are highly prone to healing failure, thereby increasing morbidity and additional treatment costs and placing an economic burden on patients and health systems.^11,15,17

TERM approaches have been studied and proposed as promising alternatives to improve the quality of tendon healing.^18,19 The fields of engineering, nanotechnology, molecular biology, and materials science are used alone or in combination with cells, scaffolds, and bioactive molecules in various TERM approaches.¹⁵ Despite showing great potential, tendon argumentation suffers from limited evidence in the literature to support the clinical use of various scaffold biomaterials.²⁰ This is partly because there is a poor understanding of the basic biology of tendon development, signal transduction, mechanotransduction, and mechanisms underlying tendon pathogenesis and healing and limited translational animal models and well-designed preclinical studies, all because there are only a few researchers working in this area.^21–25

Tendon development, histology, and physiology

Tendons together with muscle, muscle connective tissue, ligament, bone, nerves, and blood vessels are part of the musculoskeletal system, which is vital for structural support, locomotion, and movement.^26,27 The main function of tendons is to join muscles to bones and transfer forces necessary for movement.²⁸ The embryological derivative of tendons is the ectoderm.²⁹ Tenocytes are mature tenoblasts found in the tendon that were previously thought to be the only resident cells before the discovery of tendon stem cells (TSCs).³⁰ Tenocytes and tenoblasts represent nearly 90% to 95% of the cells within the tendon, with the other 5% to 10% consisting of chondrocytes, synovial cells, and vascular cells.³¹

Tenocytes and tenoblasts are specialized fibrocytes and fibroblasts, respectively, that secrete extracellular matrices, such as collagen, proteoglycans, and other proteins.³¹ Tenocytes control the repair, maintenance, and turnover of the extracellular matrix in response to external stimuli and stress.²⁹ Tendons are mainly composed of collagen, which accounts for 70% to 80% of their dry weight, including 95% type 1 collagen and 5% type 3 collagen present in the epitenonium and endotenonium.³² Tendons have collagen fibrils that bundle to make collagen fibers, forming fascicles, and bundles of fascicles from the fascicular matrix. Endotendon contains blood vessels, lymphatics, and nerves, and its outward continuation forms the epitenon, a synovial-like membrane that prevents adhesion of the tendon to other adjacent tissues.³³

TSCs are in some ways different from tenocytes, including differences in cell marker expression, proliferative and differentiation potential, and morphology.³⁰ TSCs differentiate into adipocytes, chondrocytes, and osteocytes in vitro and form tendon-, cartilage-, and bone-like tissues in vivo.³⁴ The study by Zhang J et al. showed that low mechanical stretching at 4% stimulated the differentiation of TSCs into tenocytes, whereas stretching at 8% induced the differentiation of a sub‐population of TSCs into adipogenic, chondrogenic, and osteogenic lineages.³⁴ Therefore, understanding the mechanobiology of TSCs can potentially improve the effective repair or regeneration of injured tendons.

The microstructure of tendons also comprises connective tissue tendon sheaths, fibrous sheaths, synovial sheaths, peritendon sheaths (paratenon), reflection pulleys, and tendon bursae. These structures are specialized to enhance tendon efficiency by improving the sliding motion of the tendon tissue, reducing friction with neighboring anatomical structures, and preventing the tendon from losing its course of action during muscle contraction.³⁵

Tendon pathologies and current approaches to management

A summary of the management of tendon pathologies is shown in Table 1. Tendon injuries remain a significant cause of both work-related and sport-related injuries.¹⁵ The repair of tendon injuries is a lengthy process that frequently results in a poor structural, mechanical, and functional quality of the healed tissue. At present, the clinical options for treating tendon injuries are often unsatisfactory, especially in elderly populations.³⁵

Table 1.

Summary of the management of tendon pathologies.

Disease/etiology	Description	Current management	Potential management options
Ruptures/Trauma	Partial or complete tear with pain (may be absent), loss of function, loss of strength, and feeling of emptiness on palpation	Surgical repair, rigid casting or functional bracing, functional rehabilitation^36,37	Tendon-bone insertion repair^20,25Growth factors and cytokines, gene therapy, and tissue engineering with MSCs¹¹ or TDSCs and poly(LLA-CL)/Col scaffolds³⁸
Paratenonitis	An inflammatory reaction in the outer sheath of cells that surround the tendon.³⁹ Pain, tenderness, swelling, crepitation, and warmth (early term). For example: Achilles paratenonitis	Operative treatment⁴⁰, conservative management (ice, night braces)^39,40	Eccentric exercises, extracorporeal shockwave therapy, deproteinized hemodialysate, and topical glyceryl nitrate^24,41,42
Tenosynovitis	Disease of the synovial sheath itself. Pain, tenderness, swelling of the sheath, crepitation, and warmth (early term). For example: De Quervain disease	Infectious tenosynovitis: antibiotics and/or surgical treatment⁴³Open drainage, catheter irrigation⁴³Non-infectious: modification, splinting, glucocorticoid injections, NSAIDS, DMARDS, surgical intervention⁴⁴, or acupuncture⁴⁵	Nanomolecular interventions have the future potential of use in enhancing the healing of tendons⁴⁶
Stenosing tenosynovitis	An inflammatory condition involving the synovial sheath of a tendon.⁴⁷ Pain, crepitation, nodule on palpation, and triggering in the finger. Example: trigger finger	Conservative (corticosteroid injections⁴⁸), open surgical and percutaneous release^49,50, open debridement, irrigation, and primary wound closure⁵¹	Nanomolecular interventions have the future potential of use in enhancing the healing of tendons⁴⁶Sclerosant injections, heparin, dextrose, and aprotinin⁵²
Tendinopathy (tendinitis and tendinosis)Pathogenesis: 1) tendon cell response, 2) collagen disruption and, 3) inflammation¹¹⁹	Degeneration of tendon structure (wear and tear).Pain, localized tenderness, nodule on palpation. For example: lateral epicondylitis and rotator cuff tendinopathy.³²	An exercise-based rehabilitation program and adjunct interventions for painAdjuncts to exercise therapy: PRP injections, electrophysical agents, medications^52–54, low-energy laser therapy, NSAIDS¹⁵	Hyaluronic acid,^55,56 autologous tenocyte/fibroblast implantation⁵⁷, other cell-based therapy,²⁵ growth factors,²⁰ stem cells, and botulinum toxin⁵⁸ have unknown effects,⁵³ tendon graft augmentation²⁰
Enthesopathy	Pathology of the attachment site of tendon to the bone, tenderness, swelling at the site of attachment to bone, and pain. Example: Achilles	Physiotherapy, surgical treatment,⁵⁹ platelet-rich plasma⁶⁰	Topical nitrates ⁶¹
Contracture	Joint contracture with hardening of the tendon sheath and attachment of it to the surrounding tissues	Stretching, positioning, and splinting in addition to orthopedic surgical intervention^62,63	CCH injection, percutaneous needle fasciotomy^64–66

Mesenchymal stem cells (MSC), tendon-derived stem cells (TDSCs), l-lactic acid-co-ε-caprolactone (poly(LLA-CL)/Col), collagenase clostridium histolyticum (CCH), platelet-rich plasma (PRP), non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs).

Novel methods used in tendon augmentation

Gene therapy

In the TE of tendons, genetic vector transfer is used as a biological delivery system to deliver the encoded gene products to the site of pathology to promote the local repair and regeneration of damaged tissues.^35,67–69 Identifying and transferring genes into a local cell, resulting in the translation of the gene into specific protein-like growth factors, is the basis of this approach. Growth factors, such as vascular endothelial growth factor (VEGF), growth differentiation factor-5, platelet-derived growth factor-b (PDGF-b), and insulin-like growth factor-1 (IFG-1), are among the previously studied growth factors, and their effects have been characterized in local tendon cells.⁷⁰ Localized gene transfer allows focal post-translational protein synthesis, which leads to greater biological activity and a reduced risk of activating immune reactions.³⁵ Because of poor blood supply to joint structures, such as tendons, it is difficult to deliver therapeutics intravenously, intramuscularly, and orally without exposing the body systemically to the therapeutic agent. Therefore, local delivery methods, such as gene transfer, prove to be more advantageous.^71,72 An additional benefit of using a gene-therapy, tissue-engineered approach to affect tendon healing is that it allows the physician to select specific growth factors in the tendon-healing cascade from well-documented sources.⁷⁰

An alternative novel approach to using pure vectors is the application of gene-modified sutures, as demonstrated by Zhou et al.⁷³ Plasmids, such as pEGFP-bFGF, are loaded onto nanoparticles to form nanoparticle/plasmid complexes, and then the complexes are attached to the surface of polydopamine-modified sutures to prepare nanoparticle/plasmid complex-coated sutures, which are then used for tendon repair to promote tendon healing. The outcome of their study showed that gene-modified sutures (nanoparticle/pEGFP-bFGF and pEGFP-VEGFA complex-coated) improved tendon healing by increasing tendon healing strengths, enhancing gliding function, and inhibiting adhesion formation without adverse effects on host tissues.⁷³ Table 2 summarizes studies on novel methods applied in tendon management.

Table 2.

Novel methods applied in tendon management.

Method	Key properties	Comment	Citation
a. Tendon 3D bioprinting methods ○ Extrusion‐based bioprinting ○ Inkjet bioprinting ○ Laser‐assisted bioprinting ○ Stereolithography	Cellular-based bioinksTendon scaffoldsHuman tenocytesBioprinters, bioreactors	Tendon 3D bioprinting has the potential to improve in vivo biocompatibility, cell cytoskeleton alignment along the long axis of the tendon graft, upregulation of tendon biomarkers in cells seeded on the graft, and mechanical properties to match those of the native counterpart.	^27, ^74–76
b. Signals: growth factors and cytokines	IGF, TGF-b1, CDMP, VEGF, PDGF, PRP, FGF, rhGDF	Signaling molecules that induce cell chemotaxis, proliferation, matrix synthesis, and differentiation in normal and pathophysiological conditions, such as growth, healing, and repair.	^11,27,77,78
c. Cell therapy	Tenocytes, pluripotent stem cells, TSCs	Very promising, but current problems faced are the identification and extraction of cells and identification of cell markers of these cells to easily manipulate them.	^10, ^79–81
d. Scaffolds (i) biological, (ii) synthetic and (iii) composites	Collagen, chitosan, PGA, PLA, PLGA, CaP, TCP, HA, silk proteoglycan, glycoprotein, fibronectin, and thrombospondin	Function as a provisional template for the interactive trafficking of cells and the creation of the extracellular matrix, offering structural support for the freshly made tissue. The scaffold should mimic the native tissue’s mechanical function, topography, geometry, and porosity to recreate the native microenvironment and help the adhesion, growth, and differentiation of the populating cells.	^33,82
e. Gene therapy: vector and or hybrid ○ Nanoparticle/pEGFP-bFGF, ○ pEGFP-VEGFA ○ Adenovirus ○ Adeno-associated ○ virus ○ Retrovirus ○ Lentivirus	DNA genomeDouble-strandedNanoparticles	Nanoparticle/plasmid complexes have a high transfection efficiency. They improve tendon healing by increasing tendon healing strengths, enhancing gliding function, and inhibiting adhesion formation without adverse effects on host tissues.	In vitro: ^73,83 In vivo: ^83,84
	Non-integratingMultiple serotypesDouble-strandedDNA genome	Straightforward production, efficient, transduces non-dividing cells, wide host range, inflammatory, antigenicWidely used in clinical trials,⁷³ with one well-publicized death	In vivo: ^85–87
	Recombinant AAV is non-integratingWild-type AAV has a single-stranded DNA genomeMultiple serotypes	Transduces non-dividing cells, wild-type AAV causes no known disease, non-inflammatory, difficult to produce, small carrying capacityPossible to engineer AAV with a double-stranded DNA genomeIncreasingly popular for clinical trials because of safety⁷³	In vivo: ^88–91
	RNA genomeIntegrating	Straightforward to produce amphotropic virus and has a wide host rangeTransduction requires host cell division, risk of insertional mutagenesisUsually used in ex vivo gene delivery, has been widely used in clinical trials, insertional mutagenesis has caused leukemia⁷³	In vivo: ^70,92
	RNA genomeA wild-type virus is integrating	Transduces non-dividing cells, very high levels of transgene expressionRisk of insertional mutagenesis, but non-integrating vectors developedIncreasing use in clinical trials⁷³	In vivo: ^93,94

Extracellular matrix (ECM), insulin-like growth factor (IGF), ribonucleic acid (RNA), deoxyribonucleic acid (DNA), transforming growth factor-beta 1 (TGF-b1), cell-derived microparticles (CDMPs), vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), platelet-rich plasma (PRP), fibroblast growth factor (FGF), recombinant human growth and differentiation factor (rhGDF), tendon stem cells (TSCs), polyglycolic acid (PGA), poly-dl-lactic-co-glycolic acid (PLGA), poly-l-lactic acid (PLLA), polylactic acid (PLA), hydroxyapatite (HA), tricalcium phosphate (TCP), calcium phosphate (CaP), adeno-associated virus (AAV), vascular endothelial growth factor-A (VEGFA), basic fibroblast growth factor (bFGF), plasmid enhanced green fluorescent protein (pEGFP).

Cell therapy

Cells are among the three pillar components of TERM. Stem cells, sometimes called “medicinal stem cells,” work effectively as growth factor factories or drugstores in vivo.⁹⁵ Stem cells can repopulate the injured tissue and stimulate the body’s healing properties. In tendon TE, tenocytes, TSCs, bone marrow-derived mesenchymal stem cells, MSCs, pluripotent stem cells, and embryonic stem cells are the most commonly used and most promising. The current problems faced in TE cell therapy are the identification and extraction of these cells and the identification of cell markers to easily manipulate them for a better understanding of tendon pathophysiology. A 2010 study reported that TSCs differed from tenocytes in morphology in culture, proliferative potential, stem cell marker expression, and differentiation potential.³⁰ The application of undifferentiated stem cells for the repair of tendon injuries, such as bone marrow-derived mesenchymal stem cells (MSCs), adipose tissue-derived MSCs, embryonic stem cells, embryonic stem-like cells, adipose-derived nucleated cells, umbilical cord blood-derived MSCs, and peripheral blood-derived mesenchymal stem cells, has been well characterized.⁹⁶ Furthermore, the author mentions that MSCs used in tendon regeneration have the potential to recruit other MSCs or progenitor cells to the injury site by producing a variety of cytokines and paracrine factors, thereby improving the regeneration potential.

Challenges with cell therapy mainly include the efficacy evaluation of MSC therapy, which is subject to the use of appropriate control groups, severity and size of the lesion, time between injury and implantation, number of stem cells for implantation, models of tendinopathy (e.g., collagenase or surgical disruption), and opting for single or multiple injections.⁹⁶

Signals: growth factors and cytokines

Growth factors are signaling molecules that induce cell chemotaxis, proliferation, matrix synthesis, and cell differentiation in normal and pathophysiological conditions, such as growth, healing, and repair.¹¹ The regulation of these signals during tendon injury repair is of great importance, especially in controlling the amount of scar tissue production. Extensive scar tissue at the healing attachment site may predispose patients to impingement post-operatively. Important factors to consider when adding growth factors to cell culture media to trigger tenogenic differentiation are incubation time and cell type. In clinical scenarios, several modes for the delivery of growth factors to the injury site can be applied, including direct local injection and the use of impregnated sutures or scaffolds. Impregnated sutures or scaffolds are better at delivering growth factors to the specific area of injury without the overflow loss associated with local injection. However, local injection is comparatively non-invasive, simple, and quick, although growth factors delivered in this way only remain at the site for a short duration.¹¹

IGF, transforming growth factor β1 (TGF-β1), and cartilage-derived morphogenetic protein growth factor-1, -2, and -3 are equivalent to human bone morphogenic protein (BMP)-14, -13, and -12. PDGF, epidermal growth factor, platelet-rich plasma, VEGF, interleukin-10, recombinant human osteogenic protein-1, connective tissue growth factor, fibroblast growth factor (FGF), and recombinant human growth differentiation factor have all been characterized in terms of their roles in tendon injury repair.

In several studies, PDGF-stimulated DNA and matrix synthesis in tendon cells^11,14 increased the expression of cell surface integrins, which play critical roles in tendon repair.²² IGF-1 also enhances healing by increasing DNA, collagen, and glycosaminoglycan production. In vitro and in vivo studies have elucidated the ability of IGF-1 to decrease swelling and simultaneously increase cell proliferation, collagen synthesis, and DNA content.⁷⁰ FGF2 is among the most promising cell signals in tendon augmentation and has been widely reported to increase tendon/ligament revascularization, cell proliferation, and collagen production and stimulate new bone formation, accelerating tendon-to-bone healing.^83,97,98

Scaffolding

According to Mota et al., a scaffold is a material that functions as a provisional template for the interactive trafficking of cells and the creation of the extracellular matrix, offering structural support for the freshly made tissue.⁸² Tendon scaffolding material comes in three main forms: biological, synthetic, and composite.³³ Table 3 compares the types, sources, strengths, and weaknesses of scaffolding material used in tendon augmentation.

Table 3.

Comparison of scaffolding material.

Type of scaffolding	Source	Strengths	Weaknesses	Examples	Citation
Biological	Mammalian tissues, such as human, porcine, bovine, and equine	High hydrophilic propertiesLow immunological responseCell adhesive	Low mechanical propertiesDegradation-related products can be cytotoxic, and the materials are mechanically weaker than healthy musculoskeletal tissue	Collagen type I compositeChitosan	^14,16,33
Synthetic	Chemical agents	High mechanical propertiesVersatilityLarge-scale manufacturing, limited disease transmission, controlled degradation	Low hydrophilic propertiesHigh immunological responseSelective cell adhesion	Carbon, Dacron, silicone, nylon, polyester, PGAPLAPEOPLLA	^14,16,33,96
Composite	The mixture of biologicals and or syntheticsPolymer-ceramic composite materials	Can be tailored to match different mechanical properties of native tissueImproves biocompatibility and cell adhesive potential and decreases the degradation rate of scaffolds	Low degradability and poor mechanical strength	Chitosan/alginateChitosan/hyaluronic acidBovine type I, collagen, and chondroitin-6-sulfate	^14,16,33

Poly-l-lactic acid (PLLA), polyethylene oxide (PEO), polyglycolic acid (PGA), polylactic acid (PLA).

Regardless of the type, an effective scaffold should have appropriate biocompatibility, biodegradability, biokinetics, porosity, and biomechanical properties close to the target natural tissue’s predefined geometry and size.⁸² From Table 3, it is clear that all three forms of scaffolds have strengths and weaknesses. Synthetics have a great deal of versatility and high mechanical strength and hold a greater potential for high-volume industrial production than others.¹⁰⁰ However, synthetic scaffolds are relatively immunogenic, have low hydrophilic properties, and lack sufficient cell adhesive properties. Biologic scaffolds are harvested from mammalian tissues, such as human, porcine, bovine, and equine, and are the most studied type of scaffolding.¹⁰¹ Biologics have adequate cell adhesion properties, low immunogenicity, and high hydrophilicity, although their mechanical strength is the lowest. Composite scaffolding attempts to combine the advantages of biological and synthetic scaffolds, offering improved biocompatibility and lower degradability; however, its mechanical properties still present a challenge.¹⁰²

The ideal augmenting scaffold would be able to stimulate endogenous tendon tissue regeneration during degradation and reduce in vivo mechanical forces on tendon repair during post-operative healing. Biologics (extracellular matrices) have great potential in achieving this; however, current clinical evidence is limited because there are only a few well-conducted human studies in this area.^11,20 Table 4 describes the in vivo and in vitro laboratory studies on scaffolding materials in tendon augmentation.

Table 4.

In vivo and in vitro laboratory studies on scaffolding materials in tendon augmentation.

Composite/hybrid	Model	Result/scaffold properties	Cell/tissue integration	Citation
PLGA nanofiber-based scaffold	In vitro: Human rotator cuff cells	Rotator cuff fibroblasts cultured on the aligned scaffolds attached along the nanofiber long axis, whereas the cells on the unaligned scaffold were polygonal and randomly oriented.	Observations demonstrate the potential of the PLGA nanofiber-based scaffold system for functional rotator cuff repair. Moreover, nanofiber organization has a profound effect on cellular response and matrix properties and is a critical parameter for scaffold design.	¹⁰³
PLGA loaded with BMSCs	In vivo:rabbit	These results suggest that the PLGA biodegradable scaffold loaded with allogeneic BMSCs has the potential to regenerate and repair gap defects of the Achilles tendon and effectively restore its structure and function.	All wounds healed well without any apparent inflammatory reaction or apparent lymphocyte infiltration.⁹⁹	⁹⁹
Fiber-aligned nanofibrous scaffolds,PCL fiber-aligned mesh	In vivo: rats	Implanted scaffolds remained in situ without gross migration from the supraspinatus tendon during the study interval.	Scaffold attachment to the bone appeared to not be maintained. The PCL scaffolds also showed appreciable cellular infiltration and colonization at 4 and 8 weeks after injury and repair.	¹⁰⁴
DBM/dermal matrix scaffold	In vivo: rats	The application of DBM in a rat model of chronic rotator cuff degeneration did not improve the composition of the healing enthesis compared with nonaugmented controls and a commercially available scaffold.	(i) All groups demonstrated closure of the tendon-bone gap with a fibrocartilaginous interface. (ii) Dermal collagen specimens exhibited a disorganized structure with significantly more abnormal collagen fiber arrangement and cellularity than in the DBM-based repairs.	¹⁰⁵
PGA/PLA composite	In vitro: ADSCs In vivo: rabbit	After implantation in the Achilles tendonTensile strength: 4.88 ± 8.07 MPaNo report of other mechanical properties.	(i) Grossly, the implanted cell-seeded scaffold was integrated with the native tissue interference, with a smooth surface cord-like shape and less noticeable remaining material after 45 weeks.(ii) Tissue adhesions, described grossly to be less compared with the control. (iii) Parallel and more mature collagen fibers and longitudinally aligned cells present than in the control.	¹⁶

P (LLA-CL)/collagen I	In vitro: tenocytes	Young’s modulusUnseeded ∼2.2 MPaCell seeded ∼3 MPaTensile strengthUnseeded ∼3 MPaCell seeded ∼4.5 MPa	(i) Significantly higher cell proliferation in the nanoyarn scaffold compared with that in other scaffolds and the control. (ii) SEM showed spindle-shaped cells in both nanoyarn and aligned nanofiber scaffolds, while polygonal and random pattern cells were found in the randomly oriented fibers. (iii) Expression of tendon-specific ECM (type I collagen, type III collagen, decorin, tenascin-C, and biglycan) was significantly higher at 14 days in the nanoyarn group.
				¹⁶
P (LLA-CL)/ collagen I nanoyarn	In vitro: TDSCs In vivo: mouse	Mechanical stress: The dynamic group was 59.58 ± 7.81 MPaThe static group was 43.18 ± 6.58 MPaThe control group was 32.43 ± 5.27% MPaYoung’s modulus: The dynamic group was 51.99 ± 7.16 MPaThe static group was 34.76 ± 4.75 MPa. The control group was 23.30 ± 3.83 MPa	TDSCs were used in scaffold seeding with both dynamic and static culture conditions. In vitro: (i) TDSCs showed elongated fibroblast-like morphology with a significant increase in cell counts in the dynamic group at 14 days. (ii) More cell infiltration and dense matrix in the dynamic group.(iii) PCR confirmed increased tendon-related mRNA expression in the dynamic group. (iv) Western blotting showed a significant increase in the protein expression levels of collagens I and III and tenascin-C in the dynamic group. In vivo: (i) Significantly lower number of cells at 12 weeks, with greater matrix deposition and longitudinal spindle-shaped cells in the dynamic group compared with that in other groups. (ii) Collagen content was highest in the dynamic group, reaching 77.76% ± 6.82% of that in normal rabbit patellar tendon (174.31 ± 13.89 μg/mg). (iii) Collagen I expression was significantly higher in the dynamic group.	¹⁶
				¹⁶
PLA/collagen-I electrospun bundles	In vitro: tenocytes	Composite scaffolds were made from blends containing PLA/Col-l-75/25 (w/w). Young’s modulus was 98.6 ± 12.4 MPaMaximum stress was 14.2 ± 0.7 MPa	(i) Tenocytes seeded on PLA/Col-l-50/50 blends exhibited a better cell adhesion profile and more elongated morphology than those seeded on other blends.

PLA/GNP and PLA/carboxyl-functionalized carbon nanotubes (CNT-COOH)	In vitro: fibroblastsIn vivo: mouse	Young’s modulus PLA control: 3.99 ± 0.42 GPaPLA/CNT-COOH: 4.86 ± 0.47 GPaPLA/GNP: 4.92 ± 0.15 GPaTensile strength PLA control: 59.90 ± 4.93 MPaPLA/CNT-COOH: 72.22 ± 1.52 MPaPLA/GNP: 58.56 ± 3.99 MPa	(i) Both produced scaffolds supported fibroblast metabolic activity and proliferation until the final assessment point (72 hours). (ii) In vivo assessment showed a lack of any local or systemic inflammatory response using NAG and NO serum levels. (iii) No associated hepatotoxicity in the histologic assessment. (iv) Histologic assessment of explanted scaffold showed the formation of a thin capsule around the implant with homogenous granulation tissue.	¹⁶
				¹⁶
PCL/collagen-PLLA/collagen	In vitro: myoblasts, fibroblasts	Tensile strength was 0.5058 ± 0.2130 MPaThe maximum strain was 18.49% ± 8.210Young’s modulus was 7.339 ± 2.131 MPa	(i) Statistically higher viability of both myoblasts and fibroblasts in all regions of the scaffold. (ii) Scaffold could support the formation of myotubes, which is essential for normal muscle-tendon junction formation.	¹⁶
				¹⁶
Aligned PLLA nanofiber/layered chitosan-collagen hydrogel/alginate outer coating	In vitro: tenocytes	Maximum force to breakFor uncoated 2- and 3-layer scaffolds: 7.89 ± 1.5 N and 7.45 ± 0.3 NFor gel-coated 2- and 3-layer scaffolds: 4.76 ± 0.23 N and 6.49 ± 0.09 N. No report of other mechanical properties.	(i) Alginate coating was associated with significantly less attached proteins than the control. (ii) Both coated and uncoated scaffolds maintained 50% of their substance after incubation with PBS containing 10⁴ units/mL lysozyme solution. (iii) Alamar blue and DNA concentration assessment showed high cellular viability, metabolic activity, and proliferation up to 7 days after seeding. (iv) Seeded scaffolds were shown to support cellular alignment.	¹⁶

Carboxyl-functionalized carbon nanotubes (CNT-COOH), N-acetylglucosaminidase (NAG), nitric oxide (NO), poly-l-lactic acid (PLLA), polyglycolic acid (PGA), polylactic acid (PLA), graphene nanoplatelets (GNP), poly(lactide-co-glycolide) (PLGA), bone marrow stromal cells (bMSCs), demineralized bone matrix (DBM), poly(ε-caprolactone) (PCL), l-lactic acid-co-ε-caprolactone (poly(LLA-CL), deoxyribonucleic acid (DNA), tendon-derived stem cells (TDSCs), adipose-derived stem cells (ADSCs), polymerase chain reaction (PCR), phosphate-buffered saline (PBS), scanning electron microscopy (SEM).

Nanotechnology in tendon augmentation

The National Science Foundation defines nanotechnology as “the ability to understand, control, and manipulate matter at the level of individual atoms and molecules, as well as at the “supramolecular” level involving clusters of molecules (in the range of about 0.1 to 100 nm) to create materials, devices, and systems with fundamentally new properties and functions because of their small structure”.¹⁰⁶ In nanomedicine, new advancements in nano-adjuvants, NanoKnife, oncology, orthopedic drug delivery, implantable materials, vertebral disk regeneration, and diagnostic modalities have been described and currently hold a promising future in TERM.^46,107–109

The use of nanomedicine in tendon regeneration and repair is related to the individual physicochemical properties of particles and holds promise for improving extrinsic and intrinsic tendon healing with less adhesion compared with post-surgical adhesion.^46,110 Nanofibers, such as Poly (caprolactone)-Based Nanofiber Electrospun Scaffolds, have shown promising results in various tissue regeneration applications in bone, cartilage, skin, tendon, ligament, and nerve.¹¹¹ Silver nanoparticles (AgNPs) are among the most widely used nanoparticles because they have anti-microbial and anti-adhesion effects, modulate the extracellular matrix composition, and promote the proliferation of primary tenocytes to AgNPs and the production of extracellular matrix components.¹¹² An earlier study reported that a polylactic-co-glycolic acid nanofiber-based scaffold system showed potential for functional human rotator cuff repair.¹⁰³ Nanoparticles can also be used as combination therapies. For example, Zhou et al. delivered a gene therapy to modulate gene expression, enhancing tendon healing and decreasing adhesions. The researchers transfected disrupted digital flexor tendon tenocytes with miRNA plasmids complexed with polylactic-co-glycolic acid [nanoparticles to form nanoparticle/TGF-β1 miRNA plasmid (nanoparticle/plasmid)], with improved efficiency.⁸⁴ Thus, nanotechnology remains a pivotal partner of tendon augmentation technology.

3D and 4D printing/additive manufacturing (AM) in tendon/ligament augmentation

AM, loosely called 3D printing, is a computer-assisted fabricating technique that uses precise geometry and computer-aided design to produce structures with complex geometries in a wide variety of fields. This involves the controlled deposition of a binder material laid on a powder layer using various AM techniques, such as inkjet printing and laser sintering, to produce constructs of complex geometry.^82,113,114 Bioprinting is a method of AM that combines and assembles biomaterials, bioactive molecules, and cells to generate complex tissue-engineered structures.¹¹³ This technique has been widely used in TERM studies, and its application holds tremendous hope in designing and bio-fabricating organs of complex shapes and microstructures with a high degree of automation, low production cost, high speed and volume, good accuracy, and reproducibility.^82,115 Bioprinting has been applied in the manufacturing of various organs and tissues in vitro, including vascular tissues, skin, liver, neural tissue, heart, kidney, cartilage, bone, and skeletal muscles.^116–118

Although there are extremely few studies on tendon 3D bioprinting, Merceron et al. managed to bioprint a 3D complex muscle-tendon unit structure using 3D integrated organ printing technology in vitro.⁷⁵ In another rabbit model, 3D desktop printers were used to print an anterior cruciate ligament surgical implant. After 4 and 12 weeks, an in vivo assessment of rabbit anterior cruciate ligament models showed that the scaffold was full of MSCs and displayed significant bone ingrowth and bone-graft interface formation within the bone tunnel.¹¹⁹ Moreover, in an in vivo porcine study, Zhang et al. investigated mechanical and biological properties, fabrication methods for ligament-bone composite scaffolds, and problems between 3D printed ligament grafts and host bones in ligament reconstruction surgery using ligament-bone composite scaffolds. The team concluded that ligament-bone composite scaffolds established using the 3D printing technique accelerated the regeneration of the biomimetic ligament-bone interface.¹²⁰ 3D bioprinting technology can be classified into three sub-types: inkjet-based, laser-assisted, and microextrusion-based printing.⁷⁶

Extrusion-based bioprinting (also called direct ink writing) is the most commonly used type of 3D printing in TE applications and is implemented by most commercially available systems, with several distinct advantages.^76,121 Some advantages of this technique include high versatility, affordability, ease of use, multiple print heads allowing for printing multiple materials within a single construct, printability of highly viscous bioinks (30–6 × 10⁷mPa s⁻¹), and printability of structures with high cell densities (including cell spheroids). ^27,121,122 The most significant drawback of extrusion-based bioprinting is that cell viability and functions are reduced as cells are exposed to shear stress when passing through the nozzle and pressure while in the syringe before extrusion.¹²³ In addition, this method has a relatively lower printing speed and resolution, which is highly dependent on setup. Extrusion-based bioprinting has three sub-systems (pneumatic, piston, and screw driven), which makes it versatile and compatible with some hydrogels, including alginate, gelatin, chitosan, hyaluronic acid, Pluronic F-127, and polyethylene glycol.^124,125

Inkjet and laser-assisted techniques have tremendous resolutions and cell viabilities. Inkjet bioprinting is fast and cheap and has diverse applicability for different types of materials. Disadvantages of the inkjet technique include limitations to bioinks with a viscosity of 3.5 to 12 mPa s⁻¹ and low cell density (<10⁶ cells mL⁻¹).²⁷ Laser‐assisted bioprinting is a complex and expensive system with a high degree of precision and resolution that can print a high cell density (∼10⁸ cells mL⁻¹). However, it is a fast-printing system with high applicability in the micropatterning of cells and biomolecules because of its high printing resolution.¹²⁶

Stereolithography (including digital light processing) is a complex system with high applicability in multi-material bioprinting, resolution of bioprinting (∼1 µm), and cell viability (>85%). It is equivalent to extrusion bioprinting in these areas but requires a large number of cells as the entire bath volume must be filled.¹²¹ Stereolithography has high printing costs and is restricted to only photo-cross-linkable materials, a single bioink per construct, and a uniformity (both density and distribution of phenotype) of included cells.^27,121,125

Process of 3D tendon bioprinting

The process of bioprinting (Figure 1) begins with data acquisition, during which 3D models are acquired indirectly using X-ray, computed tomography, and magnetic resonance imaging techniques to scan and reconstruct or directly using computer-aided design software. Then, bioinks are carefully selected to guarantee biocompatibility, printability, and mechanical properties. The appropriate configuration of printing parameters needs to be confirmed before bioprinting. Finally, after printing, the implanted cells should create bonds and generate some structures and functions of the natural tissue/organ through physical and chemical stimulation of the target (receptors/signals).¹²⁵

Figure 1.

Illustrating the stages involved in the process of tendon bioprinting.

If 3D bioprinting can create cadaveric tendons, then it is reasonable to think that 4D bioprinting will create “living” tendons owing to automation. While 3D printing still offers more futuristic approaches, its fundamental principle faces the limitation of producing only static, non-animating constructs that lack time-dependent dimensions and ultimately fail to mimic dynamic human tissues.^127,128 In contrast, 4D bioprinting uses smart materials that exhibit changes in physical or chemical properties in a controlled and functional manner upon exposure to an external stimulus, such as heat, moisture, light, magnetic field, or pH.¹²⁹ Moreover, unlike 3D, 4D printed constructs have the five following unique properties:^129,130

Shape memory: material changes into a predefined shape in response to an external stimulus

Self-assembly: exposure to external stimulus induces the folding of chains and assembly into a preprogrammed shape

Self-actuating: automated actuation of material upon exposure to an external stimulus

Self-sensing: material detects and quantifies the exerted external stimuli

Self-healing: damage caused in the structure is repaired without any external intervention

4D printing in orthopedics is still rare. In 2018, Haleem et al.¹³¹ postulated the potential application of 4D printing in constructing smart orthopedic 3D implants, smart multi-material printing of organs, and tissue printing. Undoubtedly, 4D bioprinting technology will lead to the development of the orthopedic specialty “smart orthopedics,” which will revolutionize the management of spinal deformities, fracture fixation, joint injuries, cartilage constructs, knee replacements, and other related orthopedic applications.^132,133 Unfortunately, we did not find in vitro, in vivo, or clinical research on 4D bioprinted constructs for tendon augmentation.

Challenges faced in translational tendon research and possible solutions

The first challenge of tendon TE is the lack of adequate translational research that enhances multidisciplinary collaboration among laboratory and clinical researchers and integrates the innovative desires of the general public (patients) to form high-quality medical practices.¹³⁴ Figure 2 describes the process of translational medicine in tendon research.

Figure 2.

Process of translational research in tendon augmentation. T0 to T2 are the translational stages from basic science to human studies. T2 to T4 represent the translation of new data into clinic and health decision making.

Translational research can be divided into five levels (T0–T4), where T0 resembles the conceptual and basic research stage, T1 shapes and provides improved ideas from basic research through early investigations in humans, and T2 encompasses the creation of effective human and clinical guidelines.¹³⁴ Finally, T3 involves translating the research to practice, while T4 emphasizes outcomes and effectiveness analysis in populations.^135,136

The challenges in the production of commercial products in TERM are stage related. First, the broad diversity of TERM as a research field presents an administrative challenge at translational stage T0 as some projects may require skills from various disciplines. This fundamental barrier feeds secondarily into problems encountered in laboratory studies, such as a lack of proper manipulation and appropriate acquisition of research material (cells, cell source, scaffold materials, nanoparticles, vectors, and bioreactors).¹³⁷ In vitro/in vivo studies (T0–T2) on cell therapy may indicate challenges in the lack of specific and reliable markers that can label tendon-derived stem cells (TDSCs) in vitro and tendon stem cells in situ, posing a problem in cell source identification, cell isolation procedures, and cell culture marker expression. This makes it difficult to fully understand the functions of TDSCs.^138,139 The lack of sufficient human subjects willing to volunteer in clinical trials affects T1 to T3.

Although 3D bioprinted tendons are promising (T0–T1), considerable work is still expected both in vivo and in vitro. The technology faces challenges in bioprinting resolution, bioprinting speed (especially for vascular structures), and scaling up to large-scale cell-based therapies because of limited oxygen and nutrient supply to the innermost parts of the bioprinted structures and efficient waste product elimination. However, Ramos and Moroni believe that perfusable branched systems with smaller microvessels can help bypass this bottleneck.¹¹³

Currently, 4D bioprinting is largely conceptual (T0) in general, and it is not yet widely applied in orthopedics. There are very few laboratory studies and clinical studies on 4D printing smart orthopedics worldwide. More orthopedic research is needed in this area at all levels. The number of in vitro/in vivo studies (T0–T4) on tendon augmentation is generally limited, and there are even fewer clinical trials, indicating the slow translation of research knowledge to therapeutic products and making the evaluation of available therapeutic options difficult.^22,137 This situation is both caused by and results in ineffective therapeutics, mainly because the fundamental mechanisms that underlie the pathogenesis of tendon injuries and impaired healing are not well understood.²¹ More research funding and interdisciplinary scientific collaborations are key in TERM research T0 to T4 translation.

Commercially available scaffolds products

Commercial products are the final output of tendon TERM research (T0–T4). The ultimate product quality determines market demand¹⁴ and directly affects the research translation cycle (T0–T4) efficiency. Numerous biological and synthetic scaffolds have been developed and approved by various regulatory bodies globally, and a few studies have investigated their properties.^14,140 In general, the mechanical and biocompatibility properties of commercially available products require improvements and new approaches, as discussed in the paper. Table 5 shows a list of the most widely used biologics that are commercially available for tendon scaffolds. Table 6 shows a list of the most widely used non-biologics that are commercially available for tendon scaffolds.

Table 5.

List of most widely used biologics commercially available for tendon scaffolds.

Product	Company	Source	Regulatory approval	Citation
Allopatch HD	MTF	Human dermis	FDA	¹⁴¹
ArthroFlex	Arthrex	Human dermis	FDA	¹⁴¹
BioArthro	BioArthro	Human amniotic membrane	FDA	¹⁴¹
Connect	Tornier	Porcine dermis	FDA	¹⁴¹
Dermaspan	Biomet	Human dermis	FDA	¹⁴¹
Artelon® and Sportmesh™	Artimplant AB, Sweden and Biomet Sports Medicine (IN, USA)	Polyurethane urea polymer	Canada, Europe, FDA; Artimplant AB, Sweden	²⁰
Bio-Blanket®	Kensey Nash Corporation (PA, USA)	Bovine dermis	FDA	²⁰
CuffPatch®	Arthrotec (IN, USA)	Porcine SIS	FDA	²⁰
Gore-Tex® patch WL	Gore and Associates, Flagstaff (AZ, USA)	ePTFE	FDA	²⁰
GraftJacket®	Wright Medical (TN, USA)	Human cadaver dermis	FDA	²⁰
GraftJacket®	Dijon (France)	Terephthalic polyethylene polyester	Canada, Europe	²⁰
Leeds-Keio® or Poly-tape®	Xiros plc, Neoligaments (Leeds, UK); Yufu Itonaga Co., Ltd (Tokyo, Japan)	Polyester ethylene terephthalate	Canada, Europe, FDA	²⁰
OrthADAPT®	Pegasus Biologic Inc. (CA, USA)	Equine pericardium	FDA	²⁰
Permacol™	Zimmer (IN, USA)	Porcine dermis	FDA	²⁰
Restore™	DePuy Orthopedics (IN, USA)	Porcine SIS	US FDA	²⁰
Shelhigh No-React® Encuff Patch	Shelhigh Inc. (NJ, USA)	Bovine or porcine pericardium	FDA	²⁰
TissueMend®	Stryker Orthopedics (NJ, USA)	Fetal bovine dermis	FDA	²⁰

Food and Drug Administration (FDA), small intestinal submucosa (SIS), expanded polytetrafluoroethylene (ePTFE).

Table 6.

List of most widely used non-biologics commercially available for tendon scaffolds.

Product	Company	Source	Regulatory approval	Citation
Gore-Tex TM	WL Gore and Associates, USA	Polytetrafluoroethylene	FDA	¹⁴
Lars ligament	Ligament Augmentation andReconstruction System, Dijon, FranceJK Orthomedic Ltd, Quebec, Canada	TerephthalicPolyethylene polyester	Canada, Europe	¹⁴
Leeds–Keio® or Poly-tape	Xiros plc, Neoligaments, Leeds, UKYufu Itonaga Co. Ltd, Tokyo, Japan	Polyester ethylene terephthalate	Canada, Europe, FDA	¹⁴
X-Repair	Synthasome	PLLA from multilayer woven mesh	FDA	¹⁴¹
Biofiber	Tornier	P4HB	FDA	¹⁴¹
Biofiber-CM		P4HB with type 1 bovine collagen, Leno weave	FDA	¹⁴¹
Artelon ® and Sportmesh	Artimplant AB, SwedenBiomet Sports Medicine, IN, USA	Synthetic-absorbablepolyurethane ureapolymer	Canada, Europe, FDA

Poly-4-hydroxybut (P4HB), poly-l-lactic acid (PLLA), Food and Drug Administration (FDA).

Recommendations and future studies

The future of tendon augmentation in TE lies in the strong integration of various disciplines to translate ideas into research, followed by actual therapeutics. Although research is still limited in tendon augmentation, considerable work has been conducted on stem cell biology and functional scaffold materials. These two fields require more clinical trials to improve the available knowledge of current materials. The fields of nanotechnology and 3D/4D bioprinting are key to the future development of TE and tendons in particular¹⁴² and require more attention.

Future researchers should focus more on combined approaches among cell therapy, growth factors, gene therapy, nanotechnology, and AM. A good example is Zhou et al., who used gene-modified sutures loaded with nanoparticles to form nanoparticle/plasmid complexes to promote tendon healing. The outcomes reported by Zhou et al. were superior tendon healing strengths, enhanced gliding function, and inhibited adhesion formation without adverse effects on host tissues.⁷³ In our review, we found limited research on 3D/4D bioprinting in orthopedics and very few studies on tendon augmentation. Therefore, the authors recommend that future studies should focus on applying 3D/4D bioprinting technologies in orthopedics, especially tendon augmentation, as they hold tremendous potential.

Conclusion

We are presented with an increasing global prevalence of tendon pathologies, especially among manual laborers, the sporting community, and the elderly. However, considerable improvements in techniques of tendon repair in the past decades have not led to clinically significant progress, partly because tendons are poorly perfused, heal slowly, and frequently form scar tissue. These and other factors have led to a high failure rate of treatments, joint stiffness, morbidity, and cost burden for patients. The current tendon TE scaffolds (synthetic, biologic, or composites) on the market are static and non-animating, lacking the time-dependent dimensions and failing to mimic the dynamic tissue environment and biomechanical forces required to promote optimal tenogenic differentiation for endogenous repair and regeneration. In the future, new strategies, such as 3D/4D bioprinting, may provide a rapid and promising solution for the production of smart tendon/ligament scaffolds with self in vivo regulation in response to stimuli, animating ability, and self-healing. This would lead to the development of smart orthopedics. This narrative review reported some successful laboratory studies on cell therapy, scaffolds, 3D/4D bioprinting, gene therapy, cell signals, or their combination. To successfully develop more tendon augmentation therapies via TERM approaches, further research and clinical trial investigations are needed.

Footnotes

Author contributions

RM conceptualized and planned the article and contributed to the writing of the manuscript. MHN, MMT, and LOZ contributed, reviewed, and edited the manuscript. JDW contributed, reviewed, and revised the final work. All the authors read and approved the final version.

Declaration of conflicting interest

The authors declare that they have no competing interests.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

ORCID iDs

Rangarirai Makuku

Marcarious M. Tantuoyir

References

Suslick

KS.

Encyclopedia of physical science and technology. Sonoluminescence and sonochemistry, 3rd edn Elsevier Science Ltd, Massachusetts. 2001: 1–20.

Katari

Peloso

Orlando

Tissue Engineering and Regenerative Medicine: Semantic Considerations for an Evolving Paradigm. Frontiers in Bioengineering and Biotechnology. 2015; 2(57).

Murphy

O'Brien

Little

Schindeler

Cell-scaffold interactions in the bone tissue engineering triad. European cells & materials. 2013; 26: 120–32.

Berthiaume

Maguire

Yarmush

ML.

Tissue engineering and regenerative medicine: history, progress, and challenges.

Annual review of chemical and biomolecular engineering. 2011; 2: 403–30.

Vacanti

Tissue engineering and regenerative medicine: from first principles to state of the art. Journal of pediatric surgery. 2010; 45(2): 291–4.

Lanza

Regenerative medicine: the last 10 years. Regenerative Medicine. 2016; 11(8): 745–6.

Hafeez

d’Avanzo

Russo

Di Marzio

Cilurzo

Paolino

, et al. Tendon Tissue Repair in Prospective of Drug Delivery, Regenerative Medicines, and Innovative Bioscaffolds. Stem Cells International. 2021; 2021: 1488829.

Ruiz-Alonso

Lafuente-Merchan

Ciriza

Saenz-del-Burgo

Pedraz

JL.

Tendon tissue engineering: Cells, growth factors, scaffolds and production techniques. Journal of Controlled Release. 2021; 333: 448–86.

Mao

Fan

Wang

Huang

Guan

Sun

, et al . A Systematic Review of Tissue Engineering Scaffold in Tendon Bone Healing in vivo. Frontiers in Bioengineering and Biotechnology. 2021; 9.

10.

Lui

PPY.

Stem cell technology for tendon regeneration: current status, challenges, and future research directions.

Stem cells and cloning: advances and applications. 2015; 8:163.

11.

Longo

Lamberti

Maffulli

Denaro

Tissue engineered biological augmentation for tendon healing: a systematic review. British Medical Bulletin. 2010; 98(1): 31–59.

12.

Silva

Ferreira

Alves

Paiva

MC.

Biodegradable polymer nanocomposites for ligament/tendon tissue engineering. Journal of Nanobiotechnology. 2020; 18(1): 23.

13.

Sigal

Grande

Dines

Drakos

Biologic and Tissue Engineering Strategies for Tendon Repair. Regenerative Engineering and Translational Medicine. 2016; 2(3): 107–25.

14.

Chen

Wang

Zheng

Scaffolds for tendon and ligament repair: review of the efficacy of commercial products. Expert Rev Med Devices. 2009; 6(1): 61–73.

15.

Lipman

Wang

Ting

Soo

Zheng

Tendinopathy: injury, repair, and current exploration.

Drug design, development and therapy. 2018; 12: 591–603.

16.

Alshomer

Chaves

Kalaskar

DM.

Advances in Tendon and Ligament Tissue Engineering: Materials Perspective. Journal of Materials. 2018; 2018: 9868151.

17.

Amini

Laurencin

Nukavarapu

SP.

Bone Tissue Engineering: Recent Advances and Challenges. 2012; 40(5): 363–408.

18.

Lim

Liau

Chowdhury

Law

JX.

Current Progress in Tendon and Ligament Tissue Engineering. Tissue Engineering and Regenerative Medicine. 2019; 16(6): 549–71.

19.

Jaiswal

Yousman

Neary

Fernschild

Zolnoski

Katebifar

, et al. Tendon tissue engineering: biomechanical considerations. Biomedical Materials. 2020; 15(5): 052001.

20.

Longo

Lamberti

Maffulli

Denaro

Tendon augmentation grafts: a systematic review. British Medical Bulletin. 2010; 94(1): 165–88.

21.

Andarawis-Puri

Flatow

Soslowsky

LJ.

Tendon basic science: Development, repair, regeneration, and healing. J Orthop Res. 2015; 33(6): 780–4.

22.

Sharma

Maffulli

Tendon injury and tendinopathy: healing and repair.

The Journal of bone and joint surgery American volume. 2005; 87(1): 187–202.

23.

Salingcarnboriboon

Yoshitake

Tsuji

Obinata

Amagasa

Nifuji

, et al. Establishment of tendon-derived cell lines exhibiting pluripotent mesenchymal stem cell-like property. Experimental Cell Research. 2003; 287(2): 289–300.

24.

Kader

Saxena

Movin

Maffulli

Achilles tendinopathy: some aspects of basic science and clinical management.

British Journal of Sports Medicine. 2002; 36(4): 239–49.

25.

Lui

PP-Y

Zhang

Chan

K-M

Qin

Biology and augmentation of tendon-bone insertion repair. Journal of Orthopaedic Surgery and Research. 2010; 5(1): 59.

26.

Kardon

Development of the musculoskeletal system: meeting the neighbors.

Development. 2011; 138(14): 2855–9.

27.

Potyondy

Uquillas

Tebon

Byambaa

Hasan

Tavafoghi

, et al. Recent advances in 3D bioprinting of musculoskeletal tissues. Biofabrication. 2020.

28.

Theodossiou

Murray

Schiele

NR.

Cell-cell junctions in developing and adult tendons.

Tissue barriers. 2020; 8(1): 1695491.

29.

Bordoni

Varacallo

Anatomy, Tendons. StatPearls. Treasure Island (FL)2020.

30.

Zhang

Wang

JHC.

Characterization of differential properties of rabbit tendon stem cells and tenocytes. BMC Musculoskeletal Disorders. 2010; 11(1): 10.

31.

Kannus

Structure of the tendon connective tissue. Scandinavian Journal of Medicine & Science in Sports. 2000; 10(6): 312–20.

32.

Heybeli

Kömür

Yılmaz

Güler

Tendons and Ligaments. In: Korkusuz F, editor. Musculoskeletal Research and Basic Science. Cham: Springer International Publishing; 2016. p. 465-82.

33.

Vasiliadis

Katakalos

The Role of Scaffolds in Tendon Tissue Engineering. Journal of Functional Biomaterials. 2020; 11(4): 78.

34.

Zhang

Wang

JH-C.

Mechanobiological response of tendon stem cells: Implications of tendon homeostasis and pathogenesis of tendinopathy. Journal of Orthopaedic Research. 2010; 28(5): 639–43.

35.

Docheva

Müller

Majewski

Evans

CH.

Biologics for tendon repair. Adv Drug Deliv Rev. 2015; 84: 222–39.

36.

Gulati

Jaggard

Al-Nammari

Uzoigwe

Gulati

Ismail

, et al . Management of achilles tendon injury: A current concepts systematic review. World J Orthop. 2015; 6(4): 380–6.

37.

Park

S-H

Lee

Young

Seo

SG.

Treatment of Acute Achilles Tendon Rupture. Clin Orthop Surg. 2020; 12(1): 1–8.

38.

Han

Wang

Ding

Yuan

, et al. Tissue Engineering and Regenerative Medicine: Achievements, Future, and Sustainability in Asia. Frontiers in Bioengineering and Biotechnology. 2020; 8(83).

39.

Michaud

Achilles Injuries, Part 2: Paratenonitis and Non-Insertional Achilles Injuries.

40.

H K, M K. The operative treatment of chronic calcaneal paratenonitis. The Journal of Bone and Joint Surgery British volume. 1980;62-B(3):353-7.

41.

Messner

Wei

Andersson

Gillquist

Räsänen

Rat Model of Achilles Tendon Disorder. Cells Tissues Organs. 1999; 165(1): 30–9.

42.

Magnussen

Dunn

Thomson

AB.

Nonoperative treatment of midportion Achilles tendinopathy: a systematic review. Clinical journal of sport medicine: official journal of the Canadian Academy of Sport Medicine. 2009; 19(1): 54–64.

43.

Giladi

Malay

Chung

KC.

A systematic review of the management of acute pyogenic flexor tenosynovitis. Journal of Hand Surgery (European Volume). 2015; 40(7): 720–8.

44.

Ray

Tall

MA.

Tenosynovitis. StatPearls [Internet]. 2019.

45.

Jiang

Fang

Effectiveness and safety of tenosynovitis of the long head of the biceps brachii with acupuncture: a protocol for a systematic review and meta-analysis. Trials. 2020; 21(1).

46.

Smith

Hudson

Ponce

Rajaram Manoharan

SR.

Nanotechnology in orthopedics: a clinically oriented review. BMC Musculoskeletal Disorders. 2018; 19(1): 67.

47.

Vuillemin

Guerini

Bard

Morvan

Stenosing tenosynovitis. J Ultrasound. 2012; 15(1): 20–8.

48.

Fleisch

Spindler

Lee

Corticosteroid Injections in the Treatment of Trigger Finger: A Level I and II Systematic Review. Journal of the American Academy of Orthopaedic Surgeons. 2007; 15: 16V 171.

49.

Xie

Zhang

Q-h

Zheng

G-z

Liu

D-z

Miao

H-g

Zhang

W-f

, et al. Stenosing tenosynovitis. Der Orthopäde. 2019; 48(3): 202–6.

50.

de Quervain

On a form of chronic tendovaginitis by Dr. Fritz de Quervain in la Chaux-de-Fonds. 1895. American journal of orthopedics (Belle Mead, NJ). 1997; 26(9): 641–4.

51.

Hohendorff

Sauer

Biber

Franke

Spies

Müller

, et al. Treatment of digital pyogenic flexor tenosynovitis: single open debridement, irrigation, and primary wound closure followed by antibiotic therapy. Archives of orthopaedic and trauma surgery. 2017; 137(1): 141–5.

52.

Rees

Wilson

Wolman

RL.

Current concepts in the management of tendon disorders.

Rheumatology. 2006; 45(5): 508–21.

53.

Cardoso

Pizzari

Kinsella

Hope

Cook

JL.

Current trends in tendinopathy management. Best Practice & Research Clinical Rheumatology. 2019; 33(1): 122–40.

54.

Weinfeld

SB.

Achilles Tendon Disorders. Medical Clinics of North America. 2014; 98(2): 331–8.

55.

Abate

Schiavone

Salini

The Use of Hyaluronic Acid after Tendon Surgery and in Tendinopathies. BioMed Research International. 2014; 2014: 783632.

56.

Kumai

Muneta

Tsuchiya

Shiraishi

Ishizaki

Sugimoto

, et al . The short-term effect after a single injection of high-molecular-weight hyaluronic acid in patients with enthesopathies (lateral epicondylitis, patellar tendinopathy, insertional Achilles tendinopathy, and plantar fasciitis): a preliminary study. Journal of Orthopaedic Science. 2014; 19(4): 603–11.

57.

Long

Wang

Legrand

Chattopadhyay

Chang

Fox

PM.

Tendon Tissue Engineering: Mechanism and Effects of Human Tenocyte Coculture With Adipose-Derived Stem Cells. The Journal of Hand Surgery. 2018; 43(2): 183.e1-.e9.

58.

Cogné

Creuzé

Petit

Delleci

Dehail

de Seze

Number of botulinum toxin injections needed to stop requests for treatment for chronic lateral epicondylar tendinopathy. A 1-year follow-up study. Annals of Physical and Rehabilitation Medicine. 2019; 62(5): 336–41.

59.

Cormick

Enthesopathy – a personal perspective on its manifestations, implications and treatment. Australas J Ultrasound Med. 2010; 13(4): 19–23.

60.

Sampson

Gerhardt

Mandelbaum

Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med. 2008; 1(3–4): 165–74.

61.

Challoumas

Kirwan

Borysov

Clifford

McLean

Millar

NL.

Topical glyceryl trinitrate for the treatment of tendinopathies: a systematic review. British journal of sports medicine. 2019; 53(4): 251–62.

62.

Skalsky

McDonald

CM.

Prevention and management of limb contractures in neuromuscular diseases. Phys Med Rehabil Clin N Am. 2012; 23(3): 675–87.

63.

Rongières

Management of posttraumatic finger contractures in adults.

Hand Surgery and Rehabilitation. 2018; 37(5): 275–80.

64.

Räisänen

Karjalainen

Göransson

Reito

Kautiainen

Malmivaara

, et al. DupuytrEn Treatment EffeCtiveness Trial (DETECT): a protocol for prospective, randomised, controlled, outcome assessor-blinded, three-armed parallel 1:1:1, multicentre trial comparing the effectiveness and cost of collagenase clostridium histolyticum, percutaneous needle fasciotomy and limited fasciectomy as short-term and long-term treatment strategies in Dupuytren's contracture. BMJ Open. 2018; 8(3): e019054–e.

65.

Strömberg

Ibsen Sörensen

Fridén

Percutaneous Needle Fasciotomy Versus Collagenase Treatment for Dupuytren Contracture: A Randomized Controlled Trial with a Two-Year Follow-up. J Bone Joint Surg Am. 2018; 100(13): 1079–86.

66.

Nayar

Pfisterer

Ingari

JV.

Collagenase Clostridium Histolyticum Injection for Dupuytren Contracture: 2-Year Follow-up. Clin Orthop Surg. 2019; 11(3): 332–6.

67.

Evans

Robbins

PD.

Possible orthopaedic applications of gene therapy.

The Journal of bone and joint surgery American volume. 1995; 77(7): 1103–14.

68.

Hoffmann

Gross

Tendon and ligament engineering: from cell biology to in vivo application. Regenerative Medicine. 2006; 1(4): 563–74.

69.

Gerich

Kang

Robbins

Evans

CH.

Gene transfer to the rabbit patellar tendon: potential for genetic enhancement of tendon and ligament healing. Gene therapy. 1996; 3(12): 1089–93.

70.

Dines

Grande

Dines

DM.

Tissue engineering and rotator cuff tendon healing. Journal of Shoulder and Elbow Surgery. 2007; 16(5): S204–S7.

71.

Bandara

Robbins

Georgescu

Mueller

Glorioso

Evans

CH.

Gene transfer to synoviocytes: prospects for gene treatment of arthritis.

DNA and cell biology. 1992; 11(3): 227–31.

72.

Evans

Using genes to facilitate the endogenous repair and regeneration of orthopaedic tissues. International orthopaedics. 2014; 38(9): 1761–9.

73.

Zhou

Yang

Yan

Zhang

Wang

, et al . Gene-Loaded Nanoparticle-Coated Sutures Provide Effective Gene Delivery to Enhance Tendon Healing. Mol Ther. 2019; 27(9): 1534–46.

74.

, Wang Z, Ying Hsi Fuh J, San Wong Y, Wang W, San Thian E. Direct E-jet printing of three-dimensional fibrous scaffold for tendon tissue engineering. Journal of biomedical materials research Part B, Applied biomaterials. 2017; 105(3): 616–27.

75.

Merceron

Burt

Seol

Y-J

Kang

H-W

Lee

Yoo

, et al . A 3D bioprinted complex structure for engineering the muscle–tendon unit. Biofabrication. 2015; 7(3): 035003.

76.

Park

Gao

Cho

D-W.

Tissue-Specific Decellularized Extracellular Matrix Bioinks for Musculoskeletal Tissue Regeneration and Modeling Using 3D Bioprinting Technology. International journal of molecular sciences. 2021; 22(15): 7837.

77.

Sundelacruz

Kaplan

DL.

Stem cell- and scaffold-based tissue engineering approaches to osteochondral regenerative medicine. Semin Cell Dev Biol. 2009; 20(6): 646–55.

78.

Niu

Subramanian

Hwang

Schilling

Galloway

JL.

Tendon Cell Regeneration Is Mediated by Attachment Site-Resident Progenitors and BMP Signaling. Current Biology. 2020; 30(17): 3277–92.e5.

79.

Costa-Almeida

Calejo

Gomes

ME.

Mesenchymal Stem Cells Empowering Tendon Regenerative Therapies. International journal of molecular sciences. 2019; 20(12): 3002.

80.

Yin

Chen

Ouyang

HW.

Stem cells for tendon tissue engineering and regeneration. Expert opinion on biological therapy. 2010; 10(5): 689–700.

81.

Migliorini

Tingart

Maffulli

Progress with stem cell therapies for tendon tissue regeneration. Expert opinion on biological therapy. 2020; 20(11): 1373–9.

82.

Mota

Puppi

Chiellini

Additive manufacturing techniques for the production of tissue engineering constructs. Journal of Tissue Engineering and Regenerative Medicine. 2015; 9(3): 174–90.

83.

Yang

Shao

Zhang

Zhou

YL.

Therapeutic strategies for flexor tendon healing by nanoparticle-mediated co-delivery of bFGF and VEGFA genes.

Colloids and surfaces B, Biointerfaces. 2018; 164: 165–76.

84.

Zhou

Zhang

Zhao

Zhu

Yang

Nanoparticle-mediated delivery of TGF-β1 miRNA plasmid for preventing flexor tendon adhesion formation. Biomaterials. 2013; 34(33): 8269–78.

85.

Bolt

Clerk

Luu

Kang

Kummer

Deng

Z-L

, et al. BMP-14 gene therapy increases tendon tensile strength in a rat model of Achilles tendon injury. JBJS. 2007; 89(6): 1315–20.

86.

Lou

Manske

Aoki

Joyce

ME.

Adenovirus-mediated gene transfer into tendon and tendon sheath. Journal of Orthopaedic Research. 1996; 14(4): 513–7.

87.

Mehta

Kang

Luo

Haydon

Mass

DP.

Characterization of adenovirus-mediated gene transfer in rabbit flexor tendons. J Hand Surg Am. 2005; 30(1): 136–41.

88.

Basile

Dadali

Jacobson

Hasslund

Ulrich-Vinther

Søballe

, et al . Freeze-dried tendon allografts as tissue-engineering scaffolds for Gdf5 gene delivery. Mol Ther. 2008; 16(3): 466–73.

89.

Tang

Zhou

Liu

Wang

XT.

Gene therapy strategies to improve strength and quality of flexor tendon healing. Expert opinion on biological therapy. 2016; 16(3): 291–301.

90.

Mao

Yang

Zhou

Wang

Liu

, et al . Modulation of digital flexor tendon healing by vascular endothelial growth factor gene transfection in a chicken model. Gene therapy. 2017; 24(4): 234–40.

91.

Mao

Zhou

Wang

Liu

Tang

JB.

Adeno-associated virus-2-mediated TGF-β1 microRNA transfection inhibits adhesion formation after digital flexor tendon injury. Gene therapy. 2016; 23(2): 167–75.

92.

Hildebrand

Frank

Hart

DA.

Gene intervention in ligament and tendon: current status, challenges, future directions. Gene therapy. 2004; 11(4): 368–78.

93.

Ricchetti

Reddy

Ansorge

Zgonis

Van Kleunen

Liechty

, et al . Effect of interleukin-10 overexpression on the properties of healing tendon in a murine patellar tendon model. J Hand Surg Am. 2008; 33(10): 1843–52.

94.

Kraus

Imhoff

Reinert

Wexel

Wolf

Hirsch

, et al. Stem cells and bFGF in tendon healing: Effects of lentiviral gene transfer and long-term follow-up in a rat Achilles tendon defect model. BMC musculoskeletal disorders. 2016; 17: 148-.

95.

Stoddart

MJ.

Mesenchymal Stem Cells as a Source of Repair Cytokines: Mesenchymal Stem Cells as the Conductor. JAAOS – Journal of the American Academy of Orthopaedic Surgeons. 2015; 23(7): 452–3.

96.

Shojaee

Parham

Strategies of tenogenic differentiation of equine stem cells for tendon repair: current status and challenges. Stem Cell Research & Therapy. 2019; 10(1): 181.

97.

Lee

S-H

Park

Y-B

Moon

H-S

Shim

J-S

Jung

H-S

Kim

, et al. The role of rhFGF-2 soaked polymer membrane for enhancement of guided bone regeneration. Journal of Biomaterials Science, Polymer Edition. 2018; 29(7-9): 825–43.

98.

Zhang

Deng

Tang

Chen

, et al . bFGF- and CaPP-Loaded Fibrin Clots Enhance the Bioactivity of the Tendon-Bone Interface to Augment Healing. The American journal of sports medicine. 2016; 44(8): 1972–82.

99.

Ouyang

Goh

Thambyah

Teoh

Lee

EH.

Knitted poly-lactide-co-glycolide scaffold loaded with bone marrow stromal cells in repair and regeneration of rabbit Achilles tendon. Tissue engineering. 2003; 9(3): 431–9.

100.

Eltom

Zhong

Muhammad

Scaffold Techniques and Designs in Tissue Engineering Functions and Purposes: A Review. Advances in Materials Science and Engineering. 2019; 2019:3429527.

101.

Longo

Lamberti

Petrillo

Maffulli

Denaro

Scaffolds in Tendon Tissue Engineering. Stem Cells International. 2012; 2012:517165.

102.

Islam

Shahruzzaman

Biswas

Nurus Sakib

Rashid

TU.

Chitosan based bioactive materials in tissue engineering applications-A review. Bioactive Materials. 2020; 5(1): 164–83.

103.

Moffat

Kwei

ASP

Spalazzi

Doty

Levine

HH.

Novel nanofiber-based scaffold for rotator cuff repair and augmentation. Tissue Eng Part A. 2009; 15(1): 115–26.

104.

Beason

Connizzo

Dourte

Mauck

Soslowsky

Steinberg

, et al. Fiber-aligned polymer scaffolds for rotator cuff repair in a rat model. Journal of shoulder and elbow surgery. 2012; 21(2): 245–50.

105.

Thangarajah

Henshaw

Sanghani-Kerai

Lambert

Blunn

Pendegrass

CJ.

The effectiveness of demineralized cortical bone matrix in a chronic rotator cuff tear model. Journal of shoulder and elbow surgery. 2017; 26(4): 619–26.

106.

Roco

MC.

National nanotechnology initiative-past, present, future.

Handbook on nanoscience, engineering and technology. 2007; 2.

107.

Zdrojewicz

Waracki

Bugaj

Pypno

Cabała

Medical applications of nanotechnology. Postepy higieny i medycyny doswiadczalnej (Online). 2015; 69: 1196–204.

108.

Owen

Dufès

Moscatelli

Mayes

Lovell

Katti

, et al . The application of nanotechnology in medicine: treatment and diagnostics. Nanomedicine. 2014; 9(9): 1291–4.

109.

Boisseau

Loubaton

Nanomedicine, nanotechnology in medicine. Comptes Rendus Physique. 2011; 12(7): 620–36.

110.

Oragui

Sachinis

Hope

Khan

Adesida

The use of nanotechnology in tendon regeneration and repair. Journal of stem cells. 2012; 7(2): 121–6.

111.

Wei

Tingting

Qiong

Ronghua

Chuangang

Pan

, et al . Applications of Poly (caprolactone)-Based Nanofibre Electrospun Scaffolds in Tissue Engineering and Regenerative Medicine. Current Stem Cell Research & Therapy. 2020; 15: 1–29.

112.

Parchi

Vittorio

Andreani

Battistini

Piolanti

Marchetti

, et al. Nanoparticles for Tendon Healing and Regeneration: Literature Review. Front Aging Neurosci. 2016; 8: 202-.

113.

Ramos

Moroni

Tissue Engineering and Regenerative Medicine 2019: The Role of Biofabrication—A Year in Review. Tissue Engineering Part C: Methods. 2019; 26(2): 91–106.

114.

Shirazi

SFS

Gharehkhani

Mehrali

Yarmand

Metselaar

HSC

Adib Kadri

, et al. A review on powder-based additive manufacturing for tissue engineering: selective laser sintering and inkjet 3D printing. Science and Technology of Advanced Materials. 2015; 16(3): 033502.

115.

Gleadall

Visscher

Yang

Thomas

Segal

Review of additive manufactured tissue engineering scaffolds: relationship between geometry and performance. Burns Trauma. 2018; 6: 19-.

116.

Turnbull

Clarke

Picard

Zhang

Riches

, et al. 3D biofabrication for soft tissue and cartilage engineering. Medical engineering & physics. 2020; 82: 13–39.

117.

Tyler

Jorge Alfredo

Peyton John

Batzaya

Anwarul

Maryam

, et al. Recent advances in 3D bioprinting of musculoskeletal tissues. Biofabrication. 2020.

118.

Datta

Ayan

Ozbolat

IT.

Bioprinting for vascular and vascularized tissue biofabrication. Acta biomaterialia. 2017; 51: 1–20.

119.

Liu

Xue

G-h

Sun

Shao

H-f

C-y

Gao

, et al. 3D Printing Surgical Implants at the clinic: A Experimental Study on Anterior Cruciate Ligament Reconstruction. Sci Rep. 2016; 6: 21704-.

120.

Zhang

Liu

Bian

, et al. [Fabrication and in vivo implantation of ligament-bone composite scaffolds based on three-dimensional printing technique]. Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery. 2014; 28(3): 314–7.

121.

Gillispie

Prim

Copus

Fisher

Mikos

Yoo

, et al . Assessment methodologies for extrusion-based bioink printability. Biofabrication. 2020; 12(2): 022003-.

122.

Hölzl

Lin

Tytgat

Van Vlierberghe

Ovsianikov

Bioink properties before, during and after 3D bioprinting. Biofabrication. 2016; 8(3): 032002.

123.

Derakhshanfar

Mbeleck

Zhang

Zhong

Xing

3D bioprinting for biomedical devices and tissue engineering: A review of recent trends and advances. Bioactive materials. 2018; 3(2): 144–56.

124.

Jia

Gungor-Ozkerim

Zhang

Yue

Zhu

Liu

, et al. Direct 3D bioprinting of perfusable vascular constructs using a blend bioink. Biomaterials. 2016; 106: 58–68.

125.

Lin

Development of 3D bioprinting: From printing methods to biomedical applications. Asian Journal of Pharmaceutical Sciences. 2020; 15(5): 529–57.

126.

Ventura

RD.

An Overview of Laser-assisted Bioprinting (LAB) in Tissue Engineering Applications. Medical Lasers; Engineering, Basic Research, and Clinical Application. 2021; 10(2): 76–81.

127.

Lui

Sow

Tan

Lai

4D printing and stimuli-responsive materials in biomedical aspects. Acta biomaterialia. 2019; 92: 19–36.

128.

Ashammakhi

Ahadian

Zengjie

Suthiwanich

Lorestani

Orive

, et al. Advances and Future Perspectives in 4D Bioprinting. Biotechnol J. 2018; 13(12): e1800148.

129.

Tamay

Dursun Usal

Alagoz

Yucel

Hasirci

3D and 4D Printing of Polymers for Tissue Engineering Applications.

Frontiers in bioengineering and biotechnology. 2019; 7: 164-.

130.

Yang

Gao

Recent Advances in 4D Bioprinting. Biotechnology Journal. 2020; 15(1): 1900086.

131.

Haleem

Javaid

Vaishya

4D printing and its applications in Orthopaedics. J Clin Orthop Trauma. 2018; 9(3): 275–6.

132.

Javaid

Haleem

Significant advancements of 4D printing in the field of orthopaedics. J Clin Orthop Trauma. 2020; 11(Suppl 4): S485–s90.

133.

Qasim

Chae

Lee

NY.

Advancements and frontiers in nano-based 3D and 4D scaffolds for bone and cartilage tissue engineering. Int J Nanomedicine. 2019; 14: 4333–51.

134.

Zarbin

What Constitutes Translational Research? Implications for the Scope of Translational Vision Science and Technology.

Translational Vision Science & Technology. 2020; 9(8): 22-.

135.

Surkis

Hogle

DiazGranados

Hunt

Mazmanian

Connors

, et al. Classifying publications from the clinical and translational science award program along the translational research spectrum: a machine learning approach. Journal of translational medicine. 2016; 14(1): 235.

136.

Fort

Herr

Shaw

Gutzman

Starren

JB.

Mapping the evolving definitions of translational research. Journal of clinical and translational science. 2017; 1(1): 60–6.

137.

Fatemeh Baghaie

Fatemeh

Masoumeh

Mohammad Hossein

An Introduction to Tissue Engineering and Orthopedic Applications. Journal of Orthopedic and Spine Trauma. 2020; 6(1).

138.

Lui

PPY.

Markers for the identification of tendon-derived stem cells in vitro and tendon stem cells in situ – update and future development. Stem cell research & therapy. 2015; 6(1): 106-.

139.

Lim

H-J

Yoon

KS.

Characterization of Tendon-Specific Markers in Various Human Tissues, Tenocytes and Mesenchymal Stem Cells. Tissue Engineering and Regenerative Medicine. 2019; 16(2): 151–9.

140.

Derwin

Baker

Spragg

Leigh

Iannotti

JP.

Commercial Extracellular Matrix Scaffolds for Rotator Cuff Tendon Repair: Biomechanical, Biochemical, and Cellular Properties. JBJS. 2006; 88(12): 2665–72.

141.

Ratcliffe

Butler

Dyment

Cagle

Jr. Proctor

Ratcliffe

, et al. Scaffolds for tendon and ligament repair and regeneration. Annals of biomedical engineering. 2015; 43(3): 819–31.

142.

Tissue Engineering and Regenerative Medicine 2019: The Role of Biofabrication—A Year in Review. Tissue Engineering Part C: Methods. 2020; 26(2): 91–106.

New frontiers of tendon augmentation technology in tissue engineering and regenerative medicine: a concise literature review

Abstract

Keywords

Introduction to tissue engineering and regenerative medicine (TERM)

Search strategy

TE in tendon/ligament augmentation

Tendon development, histology, and physiology

Tendon pathologies and current approaches to management

Novel methods used in tendon augmentation

Gene therapy

Cell therapy

Signals: growth factors and cytokines

Scaffolding

Nanotechnology in tendon augmentation

3D and 4D printing/additive manufacturing (AM) in tendon/ligament augmentation

Process of 3D tendon bioprinting

Challenges faced in translational tendon research and possible solutions

Commercially available scaffolds products

Recommendations and future studies

Conclusion

Footnotes

Author contributions

Declaration of conflicting interest

Funding

ORCID iDs

References